Understanding why certain brain cells are more vulnerable in Huntington’s disease
Molecular Mechanisms Underlying Cell Type-Specific Vulnerability in Huntington’s Disease
['FUNDING_OTHER'] · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · NIH-11080781
This study is looking into why some brain cells are more easily harmed in Huntington’s disease than others, using special techniques to find out what causes these cells to die, with the hope of discovering new treatments that could help people with the condition.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (nih funded) |
| Locations | 1 site (CAMBRIDGE, UNITED STATES) |
| Trial ID | NIH-11080781 on ClinicalTrials.gov |
What this research studies
This research investigates the specific reasons why certain types of brain cells are more susceptible to damage in Huntington’s disease compared to others. By utilizing advanced techniques like translating ribosome affinity purification (TRAP) and genetic screening, the researchers aim to identify the molecular mechanisms that lead to cell death and dysfunction. They are also analyzing patient tissue using single-cell sequencing to uncover the transcriptional changes associated with the disease. This comprehensive approach could provide insights into targeted therapies for Huntington’s disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Huntington’s disease, particularly those experiencing early symptoms.
Not a fit: Patients with other neurodegenerative diseases, such as Alzheimer's or Parkinson's, may not benefit directly from this research focused on Huntington’s disease.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that protect vulnerable brain cells in Huntington’s disease, improving patient outcomes.
How similar studies have performed: Previous research has shown promise in understanding cell type-specific vulnerabilities in neurodegenerative diseases, suggesting that this approach could yield valuable insights.
Where this research is happening
CAMBRIDGE, UNITED STATES
- MASSACHUSETTS INSTITUTE OF TECHNOLOGY — CAMBRIDGE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HEIMAN, MYRIAM — MASSACHUSETTS INSTITUTE OF TECHNOLOGY
- Study coordinator: HEIMAN, MYRIAM
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: age associated neurodegenerative disease, age associated neurodegenerative disorder, age dependent neurodegenerative disease, age dependent neurodegenerative disorder, age-driven neurodegenerative disorders